Drug intelligence / Profile preview

casein glycomacropeptide + amino acids

Development stage
Unknown
Lead developer
Vitaflo International
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
Administration
Oral
01

Overview

Casein glycomacropeptide (CGMP) is a bioactive sialylated phosphorylated peptide derived from milk during the cheese-making process. It is naturally low in phenylalanine, making it an ideal protein source for individuals with phenylketonuria (PKU). To ensure nutritional completeness, CGMP is supplemented with specific amino acids—typically histidine, leucine, tyrosine, arginine, and tryptophan—to create a complete protein substitute (CGMP-AA). This combination is more palatable than traditional amino acid-based formulas and is used to manage metabolic disorders like PKU, tyrosinemia, and alkaptonuria. Additionally, CGMP-AA is being investigated for its ability to modulate plasma amino acid levels and reduce dopamine precursors, potentially serving as a treatment for acute manic episodes in bipolar disorder.

Brand names
PKU Sphere 20Lacprodan CGMP-30
Other names
CGMP-AAlow-Phe casein glycomacropeptide supplemented with amino acids
02

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)

Beyond the preview

Go deeper on casein glycomacropeptide + amino acids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on casein glycomacropeptide + amino acids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call